Clinical Development, Computational Chemistry and Drugs

Sygnature Discovery accelerates global growth with major North American acquisition

Sygnature Discovery

JULY 31, 2023

Leading integrated drug discovery partner, Sygnature Discovery (“Sygnature”) has announced its acquisition of one of North America’s largest discovery Contract Research Organisations, Canada-based NuChem Sciences. Previous acquisitions made were Peak Proteins in April 2022 and SB Drug Discovery in January 2023. Marc Lebel, Pharm.

Computational Chemistry

Computational Chemistry Science Clinical Trials Pharmaceutical Companies

The Book of Nimbus

LifeSciVC

APRIL 27, 2023

The premise at the time was that putting computational chemistry in the primary position for new molecule ideation would upend the drug discovery paradigm. set up a “virtual project team,” leverage Schrödinger scientists to lead computational chemistry, and do all the wet work at CROs. It did just that.

Small Molecule

Small Molecule Computational Chemistry Engineering Clinical Development

Drug Discovery Digest

Sygnature Discovery accelerates global growth with major North American acquisition

The Book of Nimbus

Webinars

Stay Connected